The expression of PD-L1, for instance, guides the choice of the first-line therapeutic options for patients with non-oncogene-addicted NSCLC, but its reliability in distinguishing patients who will derive a significant benefit from immunotherapy from those who will not is far from being perfect [6]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.